KYMR · XBRL financial data

Kymera Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (KYMR's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	year only	10	26	4	7*	22	11	3	3*	34	65	0
Cost of revenue	year only	10	26	4	7*	22	11	3	3*	34	65	0
Research and development	53*	49	59	60	72*	80	78	74	84*	98	119	129
General and administrative	14*	14	17	15	16*	16	18	17	17*	20	21	19
Total operating expenses	67*	68	77	76	88*	97	96	95	101*	119	141	147
Operating income (loss)	(19)*	(58)	(51)	(72)	(81)*	(74)	(85)	(93)	(98)*	(84)	(76)	(147)
Other income (expense)	5*	9	9	10	10*	9	8	10	11*	15	14	15
Income tax expense (benefit)	—	—	—	—	—	—	—	—	year only	—	—	—
Net income (loss)	(14)*	(49)	(42)	(62)	(71)*	(66)	(77)	(82)	(87)*	(69)	(61)	(132)
Earnings per share, basic USD per share	(0.25)*	(0.69)	(0.58)	(0.82)	(0.88)*	(0.82)	(0.95)	(0.94)	(0.97)*	(0.71)	(0.62)	(1.32)
Earnings per share, diluted USD per share	(0.25)*	(0.69)	(0.58)	(0.82)	(0.88)*	(0.82)	(0.95)	(0.94)	(0.97)*	(0.71)	(0.62)	(1.32)
Weighted average shares, basic millions of shares	59*	71	73	76	80*	80	80	87	90*	98	98	100
Weighted average shares, diluted millions of shares	59*	71	73	76	80*	80	80	87	90*	98	98	100

Fiscal quarters (KYMR's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	110	94	68	111	120	90	336	113	357	144	124	373
Marketable securities	265	427	442	439	368	373	330	393	491	507	567	598
Marketable securities, non-current	61	224	192	361	362	312	298	473	771	895	814	675
Accounts receivable	15	0	0	0	0	—	40	—	0	—	20	—
Prepaid and other current assets	12	15	14	17	21	18	23	23	23	27	26	27
Total current assets	405	537	525	569	510	501	728	528	871	677	737	999
Property and equipment, net	48	49	52	51	50	49	49	45	43	42	40	38
Right-of-use asset	53	49	49	48	47	47	46	43	42	42	41	40
Total assets	576	868	826	1,035	978	918	1,131	1,102	1,743	1,669	1,645	1,767
Accounts payable	7	7	7	6	6	10	6	6	4	13	9	12
Accrued liabilities	34	16	24	27	35	23	28	29	42	35	48	63
Total current liabilities	86	56	62	67	68	59	88	72	83	63	71	90
Lease liability, non-current	77	76	75	74	72	71	70	68	67	66	64	62
Total liabilities	181	157	141	142	142	132	160	156	163	129	136	153
Accumulated deficit	(531)	(579)	(621)	(684)	(755)	(820)	(897)	(979)	(1,066)	(1,135)	(1,196)	(1,328)
Total stockholders' equity	395	711	685	893	836	786	971	946	1,580	1,540	1,509	1,615
Total liabilities and equity	576	868	826	1,035	978	918	1,131	1,102	1,743	1,669	1,645	1,767
Common shares outstanding (cover page) millions of shares	61	61	62	65	65	65	71	72	82	82	83	85

Fiscal quarters (KYMR's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(14)*	(49)	(42)	(62)	(71)*	(66)	(77)	(82)	(87)*	(69)	(61)	(132)
Stock-based compensation	11*	12	14*	15*	14*	14	15*	16*	14*	16	19*	19*
Depreciation and amortization	1*	1	2*	2*	2*	2	2*	2*	2*	2	2*	2*
Net cash from operating activities	8*	(40)	(43)*	(50)*	(62)*	(79)	(60)*	(27)*	(67)*	(89)	(54)*	(78)*
Purchases of property and equipment	12*	7	5*	(0)*	1*	0	1*	0*	0*	0	0*	0*
Net cash from investing activities	19*	(331)	16*	(158)*	69*	49	60*	(235)*	(394)*	(143)	20*	102*
Net cash from financing activities	2*	354	1*	251*	3*	0	246*	40*	705*	19	14*	226*
Net change in cash	29*	(16)	(26)*	43*	10*	(30)	246*	(223)*	244*	(213)	(20)*	249*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Kymera Therapeutics	373	0	(78)*	85.4M	13.1 quarters	Q3 FY26 10-QSep 30, 2026
Acadia Pharmaceuticals	322	342	12*	172.8M	—	Q3 FY26 10-QSep 30, 2026
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Xenon Pharmaceuticals	120	not reported	(95)*	96.8M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Summit Therapeutics	151	not reported	(160)*	799.8M	4.5 quarters	Q3 FY26 10-QSep 30, 2026
Cytokinetics	203	48	(124)*	139.3M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Vericel	133	85	not reported	51.0M	—	Q3 FY26 10-QSep 30, 2026
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.